Shefali Agarwal - 17 Mar 2022 Form 4 Insider Report for Epizyme, Inc. (EPZM)

Role
Executive Vice President, Chief Medical and Development Officer
Signature
/s/ John Weidenbruch, attorney-in-fact
Issuer symbol
EPZM
Transactions as of
17 Mar 2022
Transactions value $
$2,952
Form type
4
Filing time
21 Mar 2022, 18:05:06 UTC
Previous filing
09 Feb 2022
Next filing
08 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EPZM Common Stock Award $2,952 +2,331 +1.5% $1.27 158,716 28 Feb 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EPZM Stock Option (Right to Buy) Award $0 +500,000 $0 500,000 17 Mar 2022 Common Stock 500,000 $1.39 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired under the Company's 2013 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2 This option was granted on March 17, 2022 pursuant to the Company's 2013 Stock Incentive Plan with respect to 500,000 shares of Common Stock, with 25% vesting on March 17, 2023 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Executive Vice President, Chief Medical and Development Officer